

Candriam Impact One

Quarterly Report



DEC 22

Marketing communication intended for Professional Investors only



Investor Letter

Dear investors,

In the fourth quarter, the market seemed to stabilize. Exit markets are still very cautious and deal makers are benefitting from a challenging market which offers better opportunities to buy into.

Rubio

Rubio made one new investment in Solasta Bio, which develops the next generation of green insecticides. Scotland-based Solasta provides nature-inspired and biodiversity-protecting alternatives to the current generation of synthetic chemicals accounting for 94% of insect control solutions. Furthermore, the Portfolio is growing nicely. SkillLab landed its first large international clients with contracts worth EUR 10 million. Incision increased its ARR (Annual Recurring Revenues) with 40% and is showing growth progress in the US. OpenUp is growing fast, more than tripling its ARR with 10.000 users end of Q4. Lastly, MT/Sprout, a leading startup/venture capital publication has nominated 3 of Rubio's portfolio companies out of 12 nominees (OpenUp, De Warmte and Rift) for MT/Sprout's startup of the Year 2023 election!

Rubio has drawn down EUR 31.9 million or 31.9% of its committed capital and has invested in 17 companies.

Ananda

The Fund is invested in four portfolio companies at a total cost of EUR 14.6 million. There are additional EUR 11.5 million of reserves planned. The remaining value of the Fund as of 31 December 2022 was EUR 14.1 million. The fund committed EUR 2.9 million in one new investment in November 2022: Oneday, as part as EUR 5.8 million equity financing round.

As of 31 December 2022, Ananda has drawn down EUR 21.8 million or 20.0 % of its committed capital and has invested in 4 companies. They are planning to call 7% more in Q1 2023.

Yotta

Yotta's strategy based on the selection of robust SMEs and the importance of climate performance is starting to show positive outcomes. Indeed, climate performance and economic value creation are increasingly aligned. Companies will be more and more forced to show a decarbonization strategy, in alignment with the Paris Climate Agreement. Carbon sobriety increasingly determines financial value for large companies requiring less emissive suppliers to meet their scope 3 target. Yotta is actively working with their 7 SME's top management to define and support ambitious decarbonation plans. Yotta portfolio companies enjoyed strong growth in 2022. Their companies (average size weighting) revenue growth is as high as 16% in 2022.

As of the end of December, the gross multiple of Yotta portfolio is x1.2 (valuation compared to cost). The number of employees in their portfolio companies increased by 7% last year, creating high quality jobs in France. Yotta has drawn down EUR 52.4 million, or 40% of its committed capital and has invested in 7 companies.

Impact Partners

Impact Partners dedicates its investments to entrepreneurs that help promoting strong social cohesion. Today, Impact Partners is recognized in France, Spain, Germany, and Denmark. Impact Partners made no investment in Q4; however, 2 new investments were done in Q1 2023 on which we will comment in the next quarterly report. The fund is invested in 19 companies, all of which have a cross-border strategy. The average income growth of the portfolio is 18% in 2022-2023. Impact Partners has drawn down EUR 63.4 million, or 41.8% of its committed capital. They are planning to call EUR 8.4 million more in Q1 2023.

Eiffel Essentiel

Private Equity funds are playing a big role in financing the growth of clean energy companies, as the global economy is moving toward decarbonization and energy transition. . This transition is driven by a combination of factors including advances in clean energy technologies, increasing consumer demand for sustainable products and services and the need to address the negative impact of climate change. Eiffel has added one new company into building energy efficiency to the portfolio through a 15 million EUR investment in Citron. According to IEA, buildings are responsible for 40% of global energy consumption. Eiffel has also added a EUR 5 million trench to Volta.

As of the end of last year, Eiffel has drawn down EUR 86 million or 22% of its committed capital and has invested in 6 companies.

Lauxera

Lauxera has drawn 52% of its committed capital and has invested in 8 companies. Lauxera has organized its ESG Committee on the 9th of February to present an updated version of their impact methodology with all the various KPIs & goals attached to each investment.

Our Impact diversification is as follows: 43% wellbeing, 14% basic needs, 7% decent work, 18% resource security, 43% climate stability, 2% healthy ecosystems.

We are seeing increasing opportunities in Climate and Biodiversity themes, and we are currently finalizing our due diligence on a VC fund backing high impact agrifood tech solutions.

In transparency, Impact One is now invested in a total of 62 companies and our Impact performance is 9.5%. Our Impact KPI's are mainly distributed across the following SDGs: No Poverty, Zero Hunger, Good Health and Wellbeing, Quality Education, Decent Work and Economic Growth, Sustainable Cities and Communities, Responsible Consumption and Production.

The fund commitment level stands at approximately 62%.


In January, we had our first annual meeting, and we enjoyed the presence of our investors as well as of our two guest speakers Christophe Gégout, Founder and Managing Partner of Yotta, and Michael Krell, Managing Partner at Sofinnova. We thank them for their support and the insight they provided on their very inspiring thematics and deal flow.

We are very grateful to our LPs for trusting our approach.



01

Fund



Fund Terms

Name	Candriam Impact One
Legal form	FPCI
Fund's domicile	France
Financial year-end of the Fund	December 31st
Fund base currency	EUR
Investment Manager	SERENITY - Bloc B19-21 Route d'Arlon Strassen L-8009 LUXEMBOURG
CSSF AIFM License #	A00000634
Commitment Amount	32,663,320 €
A Shares subscribed (EUR 1 000 / share)	32 500 A shares
B Shares subscribed (EUR 1 000 / share)	1 633.2 B shares
First closing:	25/05/2020
Vintage year (Date of 1st capital call):	2020
Subscription period	1 year + 6 months + 6 months
Maturity	12 years
End of investment period	25 May 2024
Management Fees	0.5%
Financial Hurdle	3%
Impact Hurdle	50%





Fund Indicators

Total committed capital	EUR 32,663,320
GP commitment	0.5% of total committed capital at final closing
Contributed capital	EUR 7,500,000
History of contributions	2020 EUR 500 000 2021 EUR 3 500 000 2022 EUR 3 500 000
Net Assets	EUR 6,082,652
Net Assets + Callable Capital	EUR 31,245,972
Invested Amount + Callable Capital	EUR 30,144,994
Portfolio (cost of all acquisitions)	EUR 4,981,674
Portfolio (at valuation, including exits)	EUR 5,371,226
Distributed Capital	EUR 0
History of distributions to LPs	EUR 0
History of distributions to GPs	EUR 0
% of Fund invested since inception:	15.3%
% of contributed capital distributed to LPs	0.0%
Ratios	
<i>Distributions / Contributed Capital</i>	0.0%
<i>Net Asset / Contributed Called</i>	81.1%
<i>(Distributions + Net Asset) / Contributed Capital</i>	81.1%
<i>Distributions / Total Committed Capital</i>	0.0%



Fund Indicators

A Shares since Fund Inception

A share inception Value	EUR 1,000.00
Contributed Capital	EUR 229.62
Distributed Capital	-
Management Fees	EUR 4,47
Other Charges	11.71
Allocation to Carried Interest	-
A share Net Asset Value	EUR 186.22

Fees and New Provisions for Q4-22

Management Fees	EUR 25,181
CACEIS Fees	EUR 13,976
Audit Fees	EUR 3,030
Transaction Fees	EUR 0
Legal Fees	EUR 0.00
Organisational Expenses	EUR 0.00
Others	EUR 0.00



Fund Activity



Q4 2022

Capital Calls Sent

- › Over the quarter, no capital call was sent to LPs

Capital Calls Received

- › Over the quarter, 2 capital calls were received from :

November 25, 2022	Rubio Impact Fund II Coöperatie U.A	EUR		62,500.00
December 9, 2022	Ananda Impact Fund IV	EUR		190,618.72



Fund Activity

Q3 2022

Commitments

- › No new commitment was signed during Q4-2022

Distribution

- › N/A


Research

- › Over the course of Q3, the team has been actively working on the due diligence of an impact fund in the agrifood industry, which we expect to be closed in Q1-2023



02

Portfolio



Portfolio Valuation

Investment

Commitment

Investment Status

Position	Country	Date	Amount (EUR)	% TCC	% Membership	% Called	Cost	Valuation	Distribution	PnL	Multiple
1 Rubio Impact Fund II Coöperatie U.A	Netherlands	23/11/2020	2,500,000	7.65%	2.5%	32.0%	797,421	624,870	3,453	- 169,098	0.79x
2 Impact Croissance IV	France	17/11/2020	3,400,000	10.41%	2.2%	53.1%	1,421,200	1,135,699	-	- 285,501	0.80x
3 Lauxera Growth I S.L.P.	France	04/01/2021	2,000,000	6.12%	0.8%	74.4%	1,262,400	1,010,970	226,000	- 25,430	0.98x
4 Sofinnova Industrial Biotech II	France	12/02/2021	3,100,000	9.49%	2.0%	17.5%	465,000	361,606	-	- 103,394	0.78x
5 Yotta Smart Industry Fund	France	18/06/2021	2,600,000	7.96%	2.0%	39.7%	1,032,200	979,300	-	- 52,900	0.95x
6 Ananda Impact Fund IV	Germany	31/03/2022	2,700,000	8.27%	2.5%	20.3%	547,017	436,350	-	- 110,667	0.80x
7 Eiffel Essentiel SLP	France	25/07/2022	3,900,000	11.94%	1.1%	22.9%	893,997	822,432	-	- 71,565	0.92x
Total			20,200,000	61.8%		21.8%	6,419,235	5,371,226	229,453	- 818,555	

Net Unrealised Gain (Loss) on portfolio Investments **-EUR 818,555**

Gross Portfolio Multiple **0.9x**

% of Fund Invested since inception **21.8%**



Portfolio 1/4

Fund		Company	Investment	% Ownership	Multiple	Impact performance
Rubio Impact Fund II Coöperatie U.A						
	1	Wakuli	EUR 1,850,000	24.5%	3.1x	33.2%
	2	Mosa Meat BV	EUR 3,000,000	0.8%	1.0x	0.0%
	3	Skillab BV	EUR 1,500,000	N/A	1.0x	1.1%
	4	Incision	EUR 2,807,000	10.8%	1.1x	27.9%
	5	Litterati	EUR 493,000	N/A	0.0x	47.1%
	6	Arborea	EUR 702,000	5.6%	1.0x	0.0%
	7	Taylor	EUR 1,900,000	22.8%	1.3x	1.2%
	8	30MHz	EUR 2,500,000	18.8%	0.5x	4.1%
	9	Lingvist	EUR 2,500,000	10.0%	1.0x	4.9%
	10	DeWarmte	EUR 1,300,000	7.7%	1.0x	1.1%
	11	Microverse	EUR 1,772,000	1.1%	1.0x	2.9%
	12	Winc Academy	EUR 1,108,450	10.1%	1.0x	9.9%
	13	Novameat	EUR 1,250,000	5.1%	1.0x	0.0%
	14	Vytal	EUR 1,800,000	6.4%	1.0x	1.1%
	15	OpenUp Group	EUR 3,000,000	5.1%	1.0x	1.7%
	16	RIFT	EUR 965,000	14.5%	1.0x	0.0%
	17	Solasta	EUR 316,000	4.5%	1.0x	0.0%



Portfolio 2/4

Fund		Company	Investment	% Ownership	Multiple	Impact performance
Impact Croissance IV						
	1	Mi Cuento	EUR 1,899,998	26.7%	0.01x	25.6%
	2	Choose my Company (CMC)	EUR 1,782,906	21.3%	1.59x	36%
	3	Dans ma Culotte	EUR 2,730,120	33.8%	0.01x	25.1%
	4	Percko	EUR 3,002,896	19.5%	0.91x	13.7%
	5	Okeenea	EUR 3,000,000	45.2%	1.10x	81.9%
	6	Neuronation	EUR 2,737,767	28.0%	1.15x	13.1%
	7	Wefight	EUR 2,999,915	9.8%	1.00x	72.4%
	8	360 Medical	EUR 2,572,421	8.1%	0.75x	26.0%
	9	Top Doctors Holding	EUR 6,135,012	12.5%	1.00x	44.7%
	10	Chromaviso Holding	EUR 2,254,870	23.5%	1.01x	56.0%
	11	Abogados	EUR 1,045,311	29.7%	0.75x	22.1%
	12	Velogik	EUR 2,400,255	16.7%	0.90x	10.9%
	13	Plastic Repair System 2011	EUR 2,745,002	20.9%	0.75x	5.4%
	14	NP Medical Satelia	EUR 7,211,304	24.0%	1.0x	11.0%
	15	Eurekam	EUR 4,403,847	45.8%	1.0x	14.9%
	16	Betriebsarztsservice Holding	EUR 2,428,837	22.7%	1.0x	6.4%
	17	SAVD Holding	EUR 6,251,867	77.1%	1.0x	23.8%



Portfolio 3/4

Fund		Company	Investment	% Ownership	Multiple	Impact performance
Lauxera Growth I S.L.P						
	1	Caresyntax Corporation	EUR 8,240,000	3.0%	1.25x	5.2%
	2	Lumicks	EUR 18,220,000	5.0%	1.16x	20.1%
	3	PSIH	EUR 23,950,000	61.0%	1.02x	19.1%
	4	Lifen	EUR 18,950,000	7.0%	1.00x	10.5%
	5	Reapplix	EUR 3,100,000	6.9%	1.02x	8.0%
	6	Matrix Requirements	EUR 10,100,000	70.9%	1.06x	14.1%
	7	Veranex	EUR 12,500,000	6.9%	1.07x	7.0%
	8	VerdotIPS2	EUR 27,190,000	25.8%	1.01x	0.0%
Sofinnova Industrial Biotech II						
	1	Meiogenix	EUR 3,999,733	17.7%	1.0x	0%
	2	Elicit Plant SAS	EUR 5,999,992	26.0%	1.0x	0%
	3	GF Biochemicals	EUR 3,500,000	11.3%	1.0x	0%
	4	Prometheus	EUR 2,273,466	12.0%	1.0x	0%
	5	Seed pool Sofinnova	EUR 1,700,000	100.0%	1.0x	0%
Yotta Smart Industry Fund						
	1	Groupe R&D / Folan	EUR 4,500,000	13.5%	0.86x	0%
	2	AET Technologies	EUR 6,200,000	53.8%	0.61x	0%
	3	DBC	EUR 4,500,000	44.3%	1.36x	0%
	4	RECIF	EUR 8,608,000	66.9%	1.73x	0%
	5	Eldim	EUR 5,500,000	17.9%	1.40x	0%
	6	Chamatex	EUR 4,999,000	18.5%	1.01x	0%
	7	Wattelez	EUR 6,200,000	62.1%	1.02x	0%



Portfolio 4/4

Fund		Company	Investment	% Ownership	Multiple	Impact performance
Ananda Impact Fund IV						
	1	Closed Loop Medicine	EUR 3,566,522	9.2%	0.95x	11.7%
	2	Resourcify	EUR 4,516,560	10.7%	1.0x	35.1%
	3	Nature Metrics	EUR 3,540,415	6.7%	0.96x	0.0%
	4	OneDay	EUR 2,938,027	10.0%	1.0x	0%
Eiffel Essentiel						
	1	Volta	EUR 20,640,000	50.0%	1.2x	0.0%
	2	SPAC Transition	EUR 12,300,000	100.0%	1.2x	0.0%
	3	Re PV	EUR 3,210,000	49.2%	1.0x	0.0%
	4	Fifteen	EUR 20,260,000	13.7%	1.0x	0.0%
	5	GreenGo	EUR 7,000,000	13.9%	1.0x	0.0%
	6	Citron	EUR 15,700,000	52.0%	1.0x	0.0%



03

New Portfolio Companies



Portfolio Company Solasta



Solasta Bio develops a new class of bio-insecticides that are as effective as chemical insecticides. The company develops them for main agricultural pests (e.g. aphids, stinkbugs, diamondback moth). It is responsible for the discovery and development of new peptides and will partner with agricultural corporates (such as Bayer and Syngenta) for commercialization and distribution.

Theme	Circular Solutions
Location	Glasgow, UK
Inception	2020
Exit Perspective	No Consideration
Date of Investment	December 2022
Type	Seed
Amount Invested	EUR 316M
Commitment	EUR 316M
% Ownership	
Financials	<i>EV: EUR 316M</i> <i>Revenue: EUR 71k</i> <i>EBITDA: EUR -250k</i>

IMPACT

The solution is highly selective and only kills the target insect and is non-toxic for other beneficial insects or vertebrates. When Solasta Bio replaces chemical insecticides there will be an increase in biodiversity, ecosystem resilience and ecosystem services such as pollination.

Impact Targets

KPI 1 Filed a dossier for regulatory approval (US, EU, LatAm)

KPI 2 Proven efficacy and non-toxicity in commercial trial

SDG



Portfolio Company OneDay



OneDay is an entrepreneurial education platform that teaches individuals how to start their own business by learning from successful entrepreneurs, and gives them the option to earn an accredited MBA as a by-product.

IMPACT

Existing barriers to entrepreneurship are high (e.g. lack of funding, training, and experience while most existing support is only accessible for a few). Need to reduce gaps in equal access to mentorship and support minorities and women.


Theme	Educational Empowerment
Location	London, United Kingdom
Inception	2020
Exit Perspective	No Consideration
Date of Investment	November 2022
Type	Early Stage
Amount Invested	EUR 2.9M
Commitment	EUR 2.9M
% Ownership	10%
Financials	<i>EV: EUR 25m</i>

Impact Targets

KPI 1 -

KPI 2 -

SDG



Portfolio Company Citron



GADS (business name: Citron) designs, develops and operates a SaaS platform for management and data analysis to improve building energy efficiency and supervise building multi-technical installations. The company also provides complimentary energy efficiency consulting services by in-house engineering office.

Theme	Building Energy Efficiency
Location	France
Inception	2015
Exit Perspective	No Consideration
Date of Investment	December 2022
Type	Growth
Amount Invested	EUR 15.71M
Commitment	EUR 15.71M
% Ownership	52%
Financials	<i>EV: EUR 21m</i> <i>Revenue: EUR 4.2M</i>

IMPACT

Today's biggest issues stem from the price of energy constantly rising, regulatory constraints intensifying and the environmental impact of organizations becoming increasingly important. To overcome these three problems it is necessary to control, monitor and optimise costs and energy consumption.



Impact Targets

KPI 1 Surface area in m2 of buildings equipped with the solution

SDG




SDG Mapping 1/8

UN SDG	IMPACT THEME	KPI	Quantitative target	Company	KPI Value	Change %	Proportional %	Impact performance
1 NO POVERTY 	Financial inclusion	Number of farmers sourced from in the last 12 months	-	Wakuli	5,000			35.4%
	Access to basic goods and services	Number of schools reached by awareness campaigns	2096	Dans Ma Culotte	13	1%	0%	25%
	Underserved communities	Cumulative number of clients at risk of poverty who had their debt reduced through the services of Abogados	1798	Abogados	90	5.0%	3%	5%
	Underserved communities	Cumulative amount of debt cancelled for the customers of 1st KPI (in m EUR)	14.39	Abogados	5.6	5.7%	3%	
2 ZERO HUNGER 	Sustainable agriculture	Technology Readiness Level (TRL) # achieved	-	Arborea	5			38%
	Sustainable agriculture	Environmental footprint in CO2 equivalent emissions/kg	-	Arborea	-			
	Sustainable agriculture	Number of high tech customers	-	30MHz	48			4.1%
	Sustainable agriculture	Number of mid/low tech customers	-	30MHz	55			
3 GOOD HEALTH AND WELL-BEING 	Fitness and wellbeing	Number of blue collar equipped with protective vest	230,000	Percko	39,700	17%	9%	14%
	Reproductive health	Years of hygienic protection available to poor women through foundations / universities	99,000	Dans Ma Culotte	49,098	50%	25%	
	Ageing	Number of users completing a 10-hour digital therapy	36,645	Neuronation	9,579	26.1%	13%	13%
	Ageing	Number of patients with a prescription noticing an improvement in wellbeing	7,368	Neuronation	0	0%	0%	




SDG Mapping 3/8

UN SDG	IMPACT THEME	KPI	Quantitative target	Company	KPI Value	Change %	Proportional %	Impact performance
3 GOOD HEALTH AND WELL-BEING 	Biotechnology	Citations since investment	1,500	Lumicks	528	35%	18%	20%
	Biotechnology	IND's since investment	20	Lumicks	1	5%	3%	
	Biotechnology	SSIs avoided since investment	4,000	Caresyntax	272	7%	2%	5%
	Access to healthcare	Provider-years saved since investment	150	Caresyntax	7.7	5%	2%	
	Access to healthcare	Cost savings since investment (in eur)	21,000,000	Caresyntax	800,000	4%	1%	
	Access to healthcare	Number of reductions in surgical complications	-	Incision	14,236			33.9%
	Access to healthcare	Cumulative number of unique OpenUp users sessions	-	OpenUp	10,000			6.9%
	Access to healthcare	Cumulative number of patients accompanied in their treatment in oncology	39,030	Wefight	7,239	19%	9%	72%
	Access to healthcare	Cumulative number of patients referred to a doctor specialist	7,320	Wefight	9,240	126%	63%	
	Access to healthcare	Number of doctors registered on the platform in Medical Deserts	19,000	360 Medical	5,489	29%	14%	26%
	Access to healthcare	Number of in-app openings, intended for medical specialists, by general practitioners	322,103	360 Medical	74,139	23%	12%	
	Access to healthcare	Cumulative number of appointments made by patients based in deserts medical	537,280	Top Doctors Holding	240,791	45%	22%	45%



SDG Mapping 4/8

UN SDG	IMPACT THEME	KPI	Quantitative target	Company	KPI Value	Change %	Proportional %	Impact performance
3 GOOD HEALTH AND WELL-BEING 	Access to healthcare	Cumulative number of appointments performed by patients without private insurance	829,946	Top Doctors Holding	369,910	45%	22%	
	Access to healthcare	Cumulative number of preparations made under the supervision of Drugcam	14,000,000	Eurekam	1,080,000	8%	4%	15%
	Access to healthcare	Cumulative number of protected technicians	1,603	Eurekam	355	22%	11%	
	Access to healthcare	Cumulated number of chronically ill patients living in a medical desert	12,120	NP Medical Satelia	1,158	10%	5%	11%
	Access to healthcare	Cumulated number of chronically ill patients affected by electronic illiteracy	12,447	NP Medical Satelia	1,538	12%	6%	
	Access to healthcare	Cumulative number of medical examinations for employees at risk	145,000	Betriebsarztser vice	8,486	6%	3%	6%
	Access to healthcare	Cumulated number of interpreted calls in a medical setting	83,000	SAVD	19,244	23%	12%	24%
	Access to healthcare	Cumulative number of patients involved and supported via final stage clinical studies	2,000	Closed Loop Medecine	700	35%	12%	12%
	Access to healthcare	Number of patients receiving digital closed loop model-based care	100,000	Closed Loop Medecine	0	0%	0%	
	Access to healthcare	Provider-years saved since investment	150	PSIH	28.7	19%	19%	19%
	Access to healthcare	Number of elderly in retirement homes with circadian lights	247	Chromaviso	270	109%	55%	56%
	Access to healthcare	Number of beds in hospitals and psychiatric wards equipped with circadian lights	5,239	Chromaviso	141	3%	1%	





SDG Mapping 5/8

UN SDG	IMPACT THEME	KPI	Quantitative target	Company	KPI Value	Change %	Proportional %	Impact performance
3 GOOD HEALTH AND WELL-BEING 	Access to healthcare	Provider-years saved since investment	1,000	Lifen	98.4	10%	5%	10%
	Access to healthcare	Cost savings since investment (in eur)	10,000,000	Lifen	1,106,000	11%	6%	
	Access to healthcare	Amputations prevented since investment	500	Reapplix	60	12%	4%	8%
	Access to healthcare	Cost savings since investment (in eur)	25,000,000	Reapplix	2,994,000	12%	4%	
	Med-tech & Innovation	Provider-years saved since investment	685	Matrix Requirements	193	28%	14%	14%
	Med-tech & Innovation	Devices developed since investment	1,000	Veranex	75	8%	4%	7%
	Med-tech & Innovation	Clinical trials supported since investment	500	Veranex	32	6%	3%	
4 QUALITY EDUCATION 	Access to education	Number of books sold adapted to reading disabilities	120,632	Mi Cuento	3,782	3%	2%	26%
	Access to education	Number of new titles in adapted format	135	Mi Cuento	65	48%	24%	
	Access to education	Relevant language learning users	-	Lingvist	12,340			5.7%
	Access to education	Number of graduates who have found an international job above income threshold of USD 1.000 per month	-	Microverse	200			3.4%
	Access to education	Cumulative number of students who completed a skills course at Winc Academy	-	Winc Academy	1,104			14.2%







SDG Mapping 5/8

UN SDG	IMPACT THEME	KPI	Quantitative target	Company	KPI Value	Change %	Proportional %	Impact performance
7 AFFORDABLE AND CLEAN ENERGY 	Energy efficiency	Kiloton CO2 emissions avoided	-	Taylor	1,700			1.9%
	Energy efficiency	Tons CO2 emissions avoided	-	DeWarmte	100			1.7%
	Clean & Circular Energy	Technology Readiness Level (TLR) achieved	-	RIFT	4		0%	0.0%
	Clean & Circular Energy	Direct and Indirect CO2 footprint in kg/MWh	-	RIFT	0		0%	
8 DECENT WORK AND ECONOMIC GROWTH 	Developed world jobs	Cumulative number of completed skill profiles	-	SkillLab	1,794			1.2%
	Developed world jobs	Number of nurses equipped with protective clothing	33,000	Percko	3,335	10%	5%	
	Developed world jobs	Number of respondents being apprentices or blue collar	125,000	Choose My Company	59,021	47%	24%	36%
	Developed world jobs	Number of companies certified IMPACTINDEX	326	Choose My Company	81	25%	12%	
	Developed world jobs	Number of people hired through inclusion networks	234	Velogik	14	6%	3%	11%
	Developed world jobs	Number of FTEs that Velogik allows to create or to feed in insertion structures	108	Velogik	17	16%	8%	
	Social Insertion	Cumulated number of low-skilled workers hired and trained in Europe by PRS	204	Plastic Repair System 2011	0	0%	0%	5%
	Occupational Health and Safety	Cumulative numbers of hours of advice to improve the working environment	142,000	Betriebsarztservice	9,729	7%	3%	





SDG Mapping 6/8

UN SDG	IMPACT THEME	KPI	Quantitative target	Company	KPI Value	Change %	Proportional %	Impact performance
9 INDUSTRY, INNOVATION AND INFRASTRUCTURE 	Sustainable physical infrastructure	Substitute in HPC or paints and coatings 2 high concern substances by year 4		GF Biochemicals			0%	
	Sustainable physical infrastructure	Ability to produce internally or through sales 750,000 CMUs no later than year 4		Prometheus			0%	
10 REDUCED INEQUALITIES 	Reduced Inequalities	Cumulated Sales subcontracted to CEE in Spain (EUR)	1,528,000	Plastic Repair System 2011	164,000	11%	5%	
	Reduced Inequalities	Cumulated number of interpreted calls granting access to basic citizens' rights (employment, education and justice)	401,000	SAVD	98,223	24%	12%	
11 SUSTAINABLE CITIES AND COMMUNITIES 	Smart cities and mobility	Number of public facilities being accessible	2,375	Okeenea	2,576	108%	54%	82%
	Smart cities and mobility	Number of audio-signal devices implemented in traffic lights	78,835	Okeenea	43,701	55%	28%	
12 RESPONSIBLE CONSUMPTION AND PRODUCTION 	Resource efficiency	Regulatory approval of the product	-	Mosa Meat	0			0%
	Resource efficiency	Cost reduction in cultured meat (in %)	-	Mosa Meat	0			
	Resource efficiency	50% increase in targeted recombination events in relevant commercial specie due to the MeioGenix Technology	-	MeioGenix	0			0%
	Resource efficiency	3-fold increase in targeted meiotic recombination using MeioGenix Technology in any crop species in at least one cold recombination genomic location	-	MeioGenix	0			
	Resource efficiency	Recovery of a commercially relevant plant carrying a disease resistant trait devoid of the genetically linked negative agronomy using MeioGenix Technology	-	MeioGenix	0			
	Waste Management	Pieces of litter registered	-	Litterati	9,397,000			54.3%





SDG Mapping 7/8

UN SDG	IMPACT THEME	KPI	Quantitative target	Company	KPI Value	Change %	Proportional %	Impact performance
12 RESPONSIBLE CONSUMPTION AND PRODUCTION 	Waste Management	Number of stories of impact	-	Litterati	14			
	Waste Management	Waste under management (in EUR)	500000000	Resourcify	28,070,413	6%	3%	35.1%
	Waste Management	Number of waste streams handled via Resourcify	300	Resourcify	194	65%	32%	
	Resource efficiency	Satisfactory proof of efficacy of use of Elicit drought management products: increase yield by at least 10% compared to untreated field.		Elicit Plant			0%	0%
	Resource efficiency	Surface treated with Elicit products reaches of 4000 ha in 2022, 44000 ha in 2023 and 143000 ha in 2024		Elicit Plant			0%	
	Resource efficiency	Technology Readiness Level (TRL) # achieved	-	Novameat	6		0%	22%
	Resource efficiency	Single-use packages avoided		Vytal	2,645,197		0%	2.3%
	Resource efficiency	Average days for a reusable container to return		Vytal	73		0%	
	Environmental health	Achieved 10 recurring customers and 750 tpa of sales volume in year 3		GF Biochemicals			0%	
	Environmental health	Reach and maintain a "Living Building Challenge Red List" free chemical commitment before end of year 3		Prometheus			0%	
13 CLIMATE ACTION 	Greenhouse gas reduction	Reduce carbon emissions by 25%	TBD	Folan	0			0%
	Greenhouse gas reduction	Reduce carbon emissions by 25%	TBD	AET Group				0%




SDG Mapping 8/8

UN SDG	IMPACT THEME	KPI	Quantitative target	Company	KPI Value	Change %	Proportional %	Impact performance	
13 CLIMATE ACTION 	Greenhouse gas reduction	Reduce carbon emissions by 25%	TBD	DBC	0			0%	
	Greenhouse gas reduction	Reduce carbon emissions by 25%	TBD	Eldim	0			0%	
	Greenhouse gas reduction	Reduce carbon emissions by 25%	TBD	RECIF	0			0%	
	Greenhouse gas reduction	Reduce carbon emissions by 25%	TBD	Chamatex	0			0%	
	Greenhouse gas reduction	Reduce carbon emissions by 25%	TBD	Wattelez	0			0%	
	Greenhouse gas reduction	For 2 solvents at commercial scale level, demonstrate a 70% reduction of CO2 production. Weight: 60%			GF Biochemicals			0%	0%
	Greenhouse gas reduction	Proof of reduction of overall CO2 in concrete production of at least 50% reduction in 2 years and 75% by the end of year 3			Prometheus			0%	0%
15 LIFE ON LAND 	Healthy ecosystems	Metric tons produced of approved cultured beef	-	Mosa Meat	0				
	Healthy ecosystems	Tons of meat analogues sold by Novameat	-	Novameat	0		0%		
	Circular Solutions	Filed a dossier for regulatory approval (US, EU, LatAm)	-	Solasta	0		0%	0%	
	Circular Solutions	Proven efficacy and non-toxicity in commercial trial	-	Solasta	0		0%		




Portfolio Breakdown (1/2)


Fund Breakdown by Impact Theme*



Fund Breakdown by Type




Fund Breakdown by Geographies



Portfolio Breakdown (2/2)

Fund Breakdown by SDGs



This marketing communication is provided for information purposes only, it does not constitute an offer to buy or sell financial instruments, nor does it represent an investment recommendation or confirm any kind of transaction, except where expressly agreed. Although Candriam selects carefully the data and sources within this document, errors or omissions cannot be excluded a priori. Candriam cannot be held liable for any direct or indirect losses as a result of the use of this document. The intellectual property rights of Candriam must be respected at all times, contents of this document may not be reproduced without prior written approval.

Warning: Past performance of a given financial instrument or index or an investment service or strategy, or simulations of past performance, or forecasts of future performance does not predict future returns. Gross performances may be impacted by commissions, fees and other expenses. Performances expressed in a currency other than that of the investor's country of residence are subject to exchange rate fluctuations, with a negative or positive impact on gains. If the present document refers to a specific tax treatment, such information depends on the individual situation of each investor and may change.

In respect to money market funds, please be aware that an investment in a fund is different from an investment in deposits and that the investment's principal is capable of fluctuation. The fund does not rely on external support for guaranteeing its liquidity or stabilizing its NAV per unit or share. The risk of loss of the principal is borne by the investor.

Candriam consistently recommends investors to consult via our website www.candriam.com the key information document, prospectus, and all other relevant information prior to investing in one of our funds, including the net asset value ("NAV") of the funds. Investor rights and complaints procedure, are accessible on Candriam's dedicated regulatory webpages <https://www.candriam.com/en/professional/legal-and-disclaimer-candriam/regulatory-information/>. This information is available either in English or in local languages for each country where the fund's marketing is approved. This is a marketing communication. Please refer to the prospectus of the fund and to the key information document before making any final investment decision. According to the applicable laws and regulations, Candriam may decide to terminate the arrangements made for the marketing of a relevant fund at any time.

Information on sustainability-related aspects: the information on sustainability-related aspects contained in this communication are available on Candriam webpage <https://www.candriam.com/en/professional/market-insights/sfd/>. The decision to invest in the promoted product should take into account all the characteristics or objectives of the promoted product as described in its prospectus, or in the information documents which are to be disclosed to investors in accordance with the applicable law.

Notice to investors in Switzerland: The information provided herein does not constitute an offer of financial instruments in Switzerland pursuant to the Swiss Financial Services Act ("FinSA") and its implementing ordinance. This is solely an advertisement pursuant to FinSA and its implementing ordinance for financial instruments.

Swiss representative: CACEIS (Switzerland) SA, Route de Signy 35, CH-1260 Nyon. The legal documents as well as the latest annual and semi-annual financial reports, if any, of the investment funds may be obtained free of charge from the Swiss representative.

Swiss paying agent: CACEIS Bank, Paris, succursale de Nyon/Suisse, Route de Signy, 35, CH-1260 Nyon.

Place of performance: Route de Signy 35, CH-1260 Nyon.

Place of jurisdiction: Route de Signy 35, CH-1260 Nyon.

Specific information for investors in France: the appointed representative and paying agent in France is CACEIS Bank, Luxembourg Branch, sis 1-3, place Valhubert, 75013 Paris, France. The prospectus, the key investor information, the articles of association or as applicable the management rules as well as the annual and semi-annual reports, each in paper form, are made available free of charge at the representative and paying agent in France.

Specific information for investors in Spain: Candriam Sucursal en España has its registered office at C/ Pedro Teixeira, 8, Edif. Iberia Mart I, planta 4, 28020 Madrid and is registered with the Comisión Nacional del Mercado de Valores (CNMV) as an European Economic Area management company with a branch.

CNMV: 1493



Client relation offices

Amsterdam
Dubai
Frankfurt
Geneva
Zurich
Madrid
Milan
New York

Management centers

Luxembourg
Brussels
Paris
London

